Estrogens protect male mice from obesity complications and influence glucocorticoid metabolism

Citation for published version:
Dakin, RS, Walker, B, Seckl, JR, Hadoke, PWF & Drake, AJ 2015, 'Estrogens protect male mice from obesity complications and influence glucocorticoid metabolism' International Journal of Obesity. DOI: 10.1038/ijo.2015.102

Digital Object Identifier (DOI):
10.1038/ijo.2015.102

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
International Journal of Obesity

Publisher Rights Statement:
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Estrogens protect male mice from obesity complications and influence glucocorticoid metabolism

RS Dakin, BR Walker, JR Seckl, PWF Hadoke and AJ Drake

BACKGROUND: Although the prevalence of obesity is higher among women than men, they are somewhat protected from the associated cardiometabolic consequences. The increase in cardiovascular disease risk seen after the menopause suggests a role for estrogens. There is also growing evidence for the importance of estrogen on body fat and metabolism in males. We hypothesized that estrogen administration would ameliorate the adverse effects of obesity on metabolic parameters in males.

METHODS: Male and female C57Bl/6 mice were fed control or obesogenic (DIO) diets from 5 weeks of age until adulthood. Glucose tolerance testing was performed at 13 weeks of age. Mice were killed at 15 weeks of age and liver and adipose tissue were collected for analysis of gene expression. A second cohort of male mice underwent the same experimental design with the addition of estradiol pellet implantation or sham surgery at 6 weeks.

RESULTS: DIO males had greater mesenteric adipose deposition and more severe increases in plasma glucose, insulin and lipids than females. Treatment of males with estradiol from 6 weeks of age prevented DIO-induced increases in adipose tissue mass and alterations in glucose–insulin homeostasis. We also identified sex differences in the transcript levels and activity of hepatic and adipose glucocorticoid metabolizing enzymes. Estrogen treatment feminized the pattern of DIO-induced changes in glucocorticoid metabolism, rendering males similar to females.

CONCLUSIONS: Thus, DIO induces sex-specific changes in glucose–insulin homeostasis, which are ameliorated in males treated with estrogen, highlighting the importance of sex steroids in metabolism. Given that altered peripheral glucocorticoid metabolism has been observed in rodent and human obesity, our results also suggest that sexually dimorphic expression and activity of glucocorticoid metabolizing enzymes may have a role in the differential metabolic responses to obesity in males and females.

MATERIALS AND METHODS

Animals and experimental design

All animal procedures were carried out under UK Home Office license approval under the Animals (Scientific Procedures) Act, 1986, and with local ethical committee approval. C57Bl/6 mice were bred in-house and maintained under controlled conditions of light (on 0700–1900 hours) and temperature (21 °C) with free access to food and water. Males and females (n = 8 per group) were weaned aged 3 weeks onto standard chow (Special Diet Services Witham, Essex, UK) and at 5 weeks were randomly assigned by a technician not involved in the research to high-fat, high-sugar ‘obesogenic’ diet (DIO: D12328, Research Diets, New Brunswick, NJ, USA) or control diet (CON: D12331, Research Diets). D12328 induces obesity in rodents and the corresponding control diet was matched in terms of protein and micronutrient content. Animals were weighed weekly and after 8 weeks were individually housed to allow for metabolic investigation. Animals were killed aged 15 weeks by CO2 asphyxiation, between 1400 and 1600 hours following a 6-h fast and trunk blood was collected. Tissues were dissected immediately, weighed and snap frozen on dry ice. Females were killed during estrus, confirmed by vaginal smear examination showing exclusively non-nucleated cornified epithelial cells.

In a separate experiment, pre-pubertal C57Bl/6 mice of both sexes were killed following weaning (3–4 weeks of age; n = 7 per group), after a physical examination to exclude puberty (vaginal opening in females and observed in rodent and human obesity, we also sought to explore the potential role of sex differences in glucocorticoid metabolism.
RESULTS

Effects of DIO on glucose homeostasis, lipids and plasma corticosterone in males and females

Consumption of an obesogenic diet caused a significant increase in body weight in males (Figure 1a) and an increase in adipose tissue weights in both the sexes (Figure 1b). Plasma triglyceride concentrations were lower in CON females compared with males (Table 2) but plasma cholesterol and plasma and hepatic triglyceride concentrations were similarly increased by DIO in both the sexes (Table 2). DIO increased plasma concentrations of glucose (Figure 1c) and insulin (Figure 1d) following a glucose load, with a substantially larger effect in males. In mice on control diet, nadir plasma corticosterone concentrations were comparable in both the sexes; however, peak concentrations were higher in females than in males (Table 2). Peak plasma corticosterone was reduced by DIO in both the sexes (Table 2).

Effects of estradiol administration in male mice

At the end of the experiment, plasma estradiol concentrations were increased in males treated with estradiol compared with the sham group, and were significantly higher in the estradiol-treated DIO group compared with all other groups (Table 3). Plasma testosterone concentrations were reduced by estradiol treatment but unaffected by diet (Table 3). Estradiol administration reduced weight gain (Figure 2a) and adipose tissue weight (Figure 2b) in both CON and DIO males. Estradiol also ameliorated the increase in plasma glucose and insulin caused by DIO (Figures 2c and d) but did not affect plasma triglyceride or cholesterol concentrations (Table 3). However, estrogen treatment reversed the DIO-associated increase in hepatic triglyceride (Table 3). Nadir plasma concentrations of corticosterone were higher in estradiol-treated males but were unaffected by DIO; peak concentrations were comparable in all the groups (Table 3).

Glucocorticoid metabolism in DIO and the effects of estrogen

Given the sex differences in circulating corticosterone levels and the fact that altered glucocorticoid metabolism may contribute to the pathogenesis of obesity and related metabolic disorders,15 we proceeded to measure transcript and expression levels of glucocorticoid metabolizing enzymes including 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), which reactivates glucocorticoids from their inert 11-keto metabolites and the levels of the A-ring reductases (5α- and 5β-reductase, which convert glucocorticoids into their dihydro metabolites). Females had lower hepatic transcript levels of 5α-reductase and higher transcript levels of 5β-reductase than males (Figure 3a). There was a trend for females to have higher hepatic transcript levels of 11β-HSD1 than males (P = 0.057; Figure 3a) but there were no differences in hepatic enzyme activity (Figure 3b). In subcutaneous fat, although there were no sex differences in transcript levels of 11β-HSD1 (Figure 3c), enzyme activity was lower in females compared with males (Figure 3d). DIO increased hepatic transcript levels of 11β-HSD1 in males but not in females (Figure 3a),

| Gene accession number | Primer sequence (5′-3′) | Probe number |
|-----------------------|-------------------------|--------------|
| Sr reductase (5αR)    | For—gggaaacgctgataaaatccc | 41           |
| (NM_175283.3)         | Rev—ccagagtcctccaaaata  |              |
| 5β-reductase (5βR)    | For—gaaaggacgcaaaaggggt | 103          |
| (NM_145364.2)         | Rev—gggatctgctggtattccaa |              |
| 11β-hydroxysteroid    | For—tctacaagcaatgccagcag | 1            |
| dehydrogenase type 1  | Rev—gcccaagctgaaatccttc  |
| (11β-HSD1)            |                        |
| (NM_008288.2)         |                        |              |

Statistical analysis

Data presented are mean ± s.e.m. Numbers were based on our previous studies.20 Statistical analysis was carried out by t-testing, two-way or repeated measures analysis of variance as appropriate. Data were normally distributed and groups compared had similar variances. Values were considered different when P < 0.05.
although there were no changes in hepatic enzyme activity (Figure 3b). There was no effect of DIO on hepatic transcript levels of 5α-reductase or 5β-reductase in either sex (Figure 3a). In subcutaneous adipose tissue, DIO reduced 11β-HSD1 expression (Figure 3c) and activity (Figure 3d) in both the sexes.

To investigate when the sex differences in glucocorticoid metabolizing enzymes became apparent, a cohort of mice were killed before puberty (when sex-steroid concentrations are low) and enzyme expression and activity were determined. In pre-pubertal mice, there was a trend for a lower expression of hepatic 5α-reductase in females (Figure 4a), but no differences in the expression of hepatic 5β-reductase or in the expression or activity of 11β-HSD1 (Figures 4a and b). Furthermore, expression and activity of 11β-HSD1 in adipose tissue were comparable in male and female pre-pubertal mice (Figures 4c and d).

In adult males, estradiol increased hepatic transcript levels, but not enzyme activity, of 11β-HSD1 (Figures 5a and b). Analysis by two-way analysis of variance revealed an effect of estradiol to reduce hepatic transcript levels of 5α-reductase and increase transcript levels of 5β-reductase in both CON and DIO males (Figure 5a). In adipose tissue, by contrast with the liver, analysis by two-way analysis of variance revealed an overall effect of estradiol to reduce both the expression (Figure 5c) and activity (Figure 5d) of 11β-HSD1 in CON and DIO males. As DIO reduces both

![Figure 1](image-url)  
**Figure 1.** Effect of obesogenic diet and sex on adiposity and metabolism in C57Bl/6 mice. Male and female mice were fed control (CON) or obesogenic diet (DIO) from 5 weeks of age. (a) Body weight during the study, (b) adipose mass as percentage of body weight at killing. SC, subcutaneous; Mes, mesenteric; RP, retroperitoneal; Epi, epididymal. Plasma glucose (c) and insulin (d) during a glucose tolerance test. Area under curve (AUC) glucose: male CON 1003.2 ± 97.5; male DIO 1285.2 ± 93.7; female CON 859.1 ± 65.8; female DIO 961.5 ± 126.3. AUC insulin: male CON 38.9 ± 6.9; male DIO 160.0 ± 22.3; female CON 28.9 ± 1.9; female DIO 55.7 ± 7.4. Data are mean ± s.e.m., n = 8 per group, analyzed by repeated measures analysis of variance (ANOVA) (a, c and d) and two-way ANOVA (b), repeated measures where necessary. Effect of diet **P < 0.01, ***P < 0.001; effect of sex †P < 0.05, ††P < 0.01, †††P < 0.001.

| Table 2. Concentrations of lipids and corticosterone in obese and control mice |
|----------------------------------|------------------|-------------------|----------------|-----------------|------------------|
|                                  | Males            | Females           | Effect of diet | Effect of sex   | Interaction diet and sex |
| Fasting plasma triglyceride (mmol l⁻¹) | CON DIO        |                  | P-value        | P-value         | P-value          |
|                                  | 0.57 ± 0.03     | 0.78 ± 0.05       | 0.41 ± 0.03    | 0.54 ± 0.02    | 0.000027         | 0.000005         | 0.21 |
| Total plasma cholesterol (mmol l⁻¹) | 1.71 ± 0.13     | 2.67 ± 0.23       | 1.53 ± 0.17    | 2.86 ± 0.16    | < 0.000001       | 0.55             | 0.56 |
| Hepatic triglyceride (nmol mg⁻¹)  | 27.5 ± 3.7      | 60.6 ± 8.6        | 26.5 ± 3.0     | 58.5 ± 3.8     | 0.000001         | 0.77             | 0.93 |
| Nadir plasma corticosterone (nm)  | 64.8 ± 8.0      | 70.8 ± 7.6        | 66.6 ± 14.3    | 62.1 ± 10.0    | 0.94             | 0.74             | 0.60 |
| Peak plasma corticosterone (nm)   | 282.0 ± 43.0    | 177.0 ± 26.2      | 457.3 ± 62.0   | 375.0 ± 33.1   | 0.03             | 0.00001          | 0.79 |

Male and female mice were fed control (CON) or obesogenic (DIO) diets from 5 weeks of age. Plasma lipid and corticosterone levels were measured in samples taken during metabolic tests. Hepatic triglyceride was analyzed in post-mortem tissue. Data are mean ± s.e.m., analyzed by two-way analysis of variance n = 8 per group.
expression and activity of 11β-HSD1 in adipose, resulting in lower baseline 11β-HSD1 levels, there was a much smaller relative reduction in both expression and activity in the estradiol-treated DIO group (Figures 5c and d).

DISCUSSION

Our data confirm previous reports showing that male mice are markedly more susceptible than females to the effects of an obesogenic diet.3–6 In postmenopausal women and in female animal models, lower estrogen levels are associated with increased visceral adiposity22,23 and estrogen replacement improves glucose–insulin homeostasis.24,25 We show that estrogen treatment of males is associated with an improvement in weight gain and DIO-induced metabolic changes, supporting the concept that estrogen has an important role in the control of metabolism and adiposity. There is growing evidence for a fundamental role for estrogen in the regulation of obesity and related metabolic disorders in males12–14 and recent data from rodent studies suggest that hepatic estrogen signaling has a key role in the prevention of high-fat diet-induced insulin resistance in males.26 Indeed, the aromatization of testosterone to estradiol may underpin many of the physiological effects which have generally been attributed to the action of testosterone, for example, the prevention of high-fat diet-induced insulin resistance and glucose intolerance.27–29

Table 3. Concentrations of lipids, corticosterone and testosterone in male obese and control mice treated with estradiol

|                     | Sham | Estradiol | Effect of diet | Effect of estradiol | Interaction of effects |
|---------------------|------|-----------|----------------|---------------------|-----------------------|
|                     | CON  | DIO       | P-value        | P-value             | P-value               |
| Fasting plasma triglyceride (mmol l⁻¹) | 0.55 ± 0.05 | 0.94 ± 0.09 | 0.59 ± 0.06 | 0.81 ± 0.06 | 0.000024   | 0.49 | 0.20 |
| Total plasma cholesterol (mmol l⁻¹) | 2.19 ± 0.31 | 3.59 ± 0.44 | 2.05 ± 0.22 | 3.16 ± 0.21 | 0.00016   | 0.34 | 0.62 |
| Hepatic triglyceride (nmol mg⁻¹) | 19.0 ± 2.7 | 48.8 ± 6.9 | 25.9 ± 2.8 | 27.9 ± 3.3 | 0.0005   | 0.10 | 0.0019 |
| Nadir plasma corticosterone (nmol) | 15.3 ± 3.5 | 17.0 ± 2.9 | 50.0 ± 11.7 | 39.6 ± 6.0 | 0.55   | 0.00351 | 0.41 |
| Peak plasma corticosterone (nmol) | 148.7 ± 18.1 | 178.9 ± 24.5 | 240.2 ± 35.5 | 173.1 ± 30.6 | 0.52   | 0.14 | 0.09 |
| Plasma estradiol (pg ml⁻¹) | 2.5 ± 0.4 | 2.0 ± 0.3 | 6.9 ± 1.2 | 21.6 ± 4.7 | 0.09   | <0.000001 | 0.11 |

Male mice were fed control (CON) or obesogenic (DIO) diets from 5 weeks of age and at 6 weeks of age underwent implantation of a continuous release 17β-estradiol pellet (estradiol) or sham surgery (sham). Plasma lipid and corticosterone levels were measured in samples taken during metabolic tests. Hepatic triglyceride was analyzed in post-mortem tissue. Data are mean ± s.e.m., analyzed by two-way analysis of variance, plasma estradiol concentrations were log transformed before analysis. n = 11 per sham group, 12 per estradiol group.
example, the prevention of visceral adiposity. Estrogen may also have a role in the control of hepatic lipid metabolism and hepatic lipid deposition, and estrogen treatment in DIO males abolished the DIO-induced increase in the accumulation of hepatic triglycerides. Intriguingly, this occurred in the absence of any effect of estradiol on plasma triglyceride and cholesterol concentrations. Estrogen may influence appetite and energy expenditure. Although we did not measure food intake and energy expenditure in this study, data from female rodents suggest that ovariectomy induces an increase in food intake and estrogen replacement decreases food intake. However, hyperphagia does not fully account for the changes in metabolism and development of obesity after ovariectomy. Our findings, showing the importance of estrogen signaling in regulating body weight, glucose–insulin homeostasis and hepatic triglyceride content are in agreement with studies in mice lacking the estrogen receptor (ER). Mice lacking ER have increased adipose tissue, higher fasting blood glucose and insulin and hepatic insulin resistance with altered hepatic lipid handling. Furthermore, deletion of ERα in mice blocks the antiobesity effects of estrogen replacement. Male mice lacking ER specifically in the liver show reduced insulin sensitivity. Conversely, hepatic ERα overexpression is associated with markedly reduced hepatic triglyceride content and improved insulin sensitivity.

There were sex differences in circulating corticosterone concentrations and, as in previous rodent studies, DIO reduced peak corticosterone concentrations in both the sexes, which may reflect altered peripheral glucocorticoid clearance. As altered glucocorticoid metabolism may contribute to the pathogenesis of obesity and related metabolic disorders, we hypothesized that some of the protective effects of estrogen might be due to effects on adipose and/or hepatic glucocorticoid metabolism. There are sex differences in the expression and activity of glucocorticoid metabolizing enzymes in humans, with lower expression and activity of hepatic and adipose 11β-HSD1 in females and estrogen regulates 11β-HSD1 expression and activity in the rat liver and kidney and in rodent and human adipocytes. We observed sex-specific responses of glucocorticoid metabolizing enzymes to diet-induced obesity, and estrogen therapy feminized the pattern of enzyme expression and activity in males. We observed no sex differences in the expression or activity of hepatic or adipose 11β-HSD1 in pre-pubertal mice, although there were clear sex differences in adult animals. 11β-HSD1 messenger RNA (mRNA) and activity were higher in lean males compared with females, a finding which has also been reported in humans. This predicts greater regeneration of corticosterone in adult male adipose tissue and may be a disadvantage given that mice overexpressing 11β-HSD1 in adipose tissue exhibit intra-abdominal obesity and metabolic dysfunction. The DIO-induced reduction in 11β-HSD1 mRNA and activity in subcutaneous adipose tissue that occurred in both the sexes in our study has previously been reported in male rodents and has been proposed as a protective mechanism to reduce both circulating glucocorticoid concentrations and local glucocorticoid signaling. Indeed, 11β-HSD1-knockout mice, or mice treated with selective 11β-HSD1 inhibitors, are resistant to obesity and hyperglycemia when fed a high-fat diet, although, notably, these studies were carried out in male animals. Lower adipose 11β-HSD1 in females compared with males may, therefore, contribute to the relative protection of females from the metabolic effects of obesity. Consistent with this hypothesis, the estrogen-induced reduction in adipose 11β-HSD1 mRNA and activity may be one mechanism for the protection from the metabolic consequences of high-fat diet in estrogen-treated males. However, the relative importance of changes in adipose tissue 11β-HSD1 in mediating the metabolic response to DIO remains unclear, as DIO itself is associated with a profound reduction in the expression and activity of adipose metabolism.
11β-HSD1 in both the sexes, yet the metabolic phenotype is more severe in DIO males.

Sex differences in the expression of 5α- and 5β-reductase also became apparent after puberty. As 5α-reduced glucocorticoid metabolites are active at the glucocorticoid receptor, the increased expression of 5α-reductase and lower expression of 5β-reductase in males predict increased hepatic concentrations of active glucocorticoids in males and may render them more susceptible to the effects of a high-fat diet. Indeed, in humans obesity is associated with alterations in the ratio of urinary 5α- and 5β-reduced glucocorticoid metabolites, with an increased proportion of cortisol metabolized by 5α-reduction. Estradiol treatment in males decreased hepatic 5α-reductase and increased 5β-reductase expression, resulting in a similar expression pattern to that in females. As 5β-reductase can metabolize both corticosterone and 11-dehydrocorticosterone, and its metabolites are not active at glucocorticoid receptor, this predicts reduced intrahepatic glucocorticoid signaling and may be one mechanism by which estrogen treatment resulted in protection from the metabolic consequences of exposure to a high-fat diet. Although females, DIO males and estradiol-treated males had increased hepatic 11β-HSD1 expression in comparison to lean males, this was not reflected in differences in enzyme activity. We have previously suggested that this discrepancy may reflect post-transcriptional modification. Intriguingly, the DIO-induced increase in hepatic 11β-HSD1 and the reduction in peak corticosterone were not present in the sham surgery DIO males suggesting that there may be long-term effects of surgery on glucocorticoid metabolism.

In terms of mechanisms, changes in 11β-HSD1 expression following ovariectomy and estrogen treatment in female rats could be due to reduced adiposity rather than increases in estradiol. However, both direct and indirect effects of estradiol on adipose 11β-HSD1 have been proposed: estradiol is a competitive inhibitor of 11β-HSD1 in primary cultures of rat adipocytes and higher adipose expression of 11β-HSD1 is found in postmenopausal women. In our study, the lack of sex difference in adipose and liver 11β-HSD1 expression and activity in pre-pubertal mice, when sex-steroid concentrations are low, combined with the changes with estrogen treatment in adult males are consistent with direct regulation of glucocorticoid metabolism in adipose tissue. Although estrogen may have an important influence on peripheral glucocorticoid metabolism, there is increasing evidence for the key role of insulin. In rodents, insulin sensitization ameliorates the obesity-induced changes in hepatic A-ring reductase expression and activity, and in humans, intravenous insulin acutely increases cortisol regeneration by 11β-HSD1 and cortisol production by 11β-HSD1 parallels the change in circulating insulin concentrations following meals. Thus, the changes in hepatic and adipose glucocorticoid metabolism seen in females and in estrogen-treated males may additionally represent a downstream effect of the marked improvement in insulin sensitivity. Finally, the changes induced by estrogen treatment may also be attributed to reduced testosterone levels in both CON and DIO males. However, a recent study in humans in which endogenous testosterone and estradiol were suppressed pharmacologically suggests that, whereas androgen deficiency may account for decreases in lean mass, estrogen deficiency is responsible for increases in body fat. Nevertheless, altered estrogen/androgen balance may still

Figure 4. Sex differences in hepatic and subcutaneous fat glucocorticoid metabolism in pre-pubertal mice. Male and female mice were killed aged 3–4 weeks, before signs of puberty, and liver and subcutaneous adipose were collected. mRNA abundance of glucocorticoid metabolizing genes was assessed using real-time PCR in liver (a) and subcutaneous fat (c) and 11β-HSD1 activity determined in liver (b) and subcutaneous fat (d). Data are mean ± s.e.m., n = 7 per group, analyzed by Student’s t-test.
be of importance in the maintenance of normal physiology and future studies in which testosterone levels are maintained at physiological levels would help to determine the relative importance of estrogens versus androgens.

Our hypothesis for this study was that estrogen treatment in males would ameliorate the adverse effects of diet-induced obesity on metabolic parameters. Consequently, we did not assess the effects of administration of estradiol in females. Estrogens may also have a role in mediating glucose–insulin homeostasis in women and estrogen deficiency is associated with an increasing risk of obesity, the metabolic syndrome and type 2 diabetes.\textsuperscript{29} In postmenopausal women, the administration of estrogen can improve glucose homeostasis, insulin sensitivity and lipid profile.\textsuperscript{56–58} Studies using estrogen replacement in ovariectomized mice have shown that estrogen protects against fatty liver and may improve pathway-selective insulin resistance.\textsuperscript{28}

In conclusion, our data support the importance of estrogen in the apparent protection of females from the deleterious effects of exposure to an obesogenic diet and provide further evidence for the suggestion that manipulating estrogen signaling pathways may represent an alternative/additional approach to the management of the complications of obesity in males. In addition, they suggest that sexually dimorphic expression and activity of glucocorticoid metabolizing enzymes may contribute to gender differences in metabolic responses to diet-induced obesity. Understanding the molecular basis of sex differences in disease risk may provide new approaches to the management of obesity-associated metabolic disease.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

Figure 5. Effect of obesogenic diet and estrogen treatment on glucocorticoid metabolism in male mice. Male mice were fed control (CON) or obesogenic (DIO) diet from 5 weeks of age and at 6 weeks underwent implantation of a continuous release 17β-estradiol pellet (estradiol) or sham surgery (sham). mRNA abundance was assessed using real-time PCR in the liver (a) and subcutaneous adipose (c). Activity of 11β-HSD1 was analyzed in samples from the same tissues (b and d). Data are mean ± s.e.m., n = 11 per sham group, 12 per estradiol group, analyzed by two-way analysis of variance. Effect of diet \( **P < 0.01, ***P < 0.001; \) effect of estradiol \( \dagger\dagger\dagger P < 0.001; \) interaction between effects \( \dagger\dagger\dagger P < 0.001.\)

ACKNOWLEDGEMENTS
We thank Jon Henderson for expert technical assistance. This work was supported a 4 year studentship from the British Heart Foundation to RSD (FS/07/063/24075). AJD was supported by a Scottish Senior Clinical Fellowship (SCD/09).

REFERENCES
1 Klein S, Allison DB, Heymsfield SB, Kelley DE, Leibel RL, Nonas C et al. Waist circumference and cardiometabolic risk: a consensus statement from Shaping America’s Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Am J Clin Nutr 2007; 85: 1197–1202.
2 Kautzky-Willer A, Handisurya A. Metabolic diseases and associated complications: sex and gender matter. Eur J Clin Invest 2009; 39: 631–648.
3 Noonan WT, Banks RO. Renal function and glucose transport in male and female mice with diet-induced type II diabetes mellitus. Proc Soc Exp Biol Med 2000; 225: 221–223.
4 Nishikawa S, Yasoshima A, Doi K, Nakayama H, Uetsuka K. Involvement of sex, strain and age factors in high fat diet-induced obesity in C57BL/6J and BALB/cA mice. Exp Anim 2007; 56: 263–272.
5 Hwang LL, Wang CH, Li TL, Chang SD, Lin LC, Chen CP et al. Sex differences in high-fat diet-induced obesity, metabolic alterations and learning, and synaptic plasticity deficits in mice. Obesity 2010; 18: 463–469.
6 Stubbins R, Holcomb V, Hong J, Núñez N. Estrogen modulates abdominal adiposity and protects female mice from obesity and impaired glucose tolerance. Eur J Nutrition 2012; 51: 861–870.
7 Maher MA, Banz WJ, Truett GE, Zemel MB. Dietary fat and sex modify heterozygote effects of the rat Fatty (fa) allele. J Nutr 1996; 126: 2487–2493.
8 Corsetti JP, Sparks JD, Peterson RG, Smith RL, Sparks CE. Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis 2000; 148: 231–241.
9 Donahue RP, Bean JA, Donahue RA, Goldberg RB, Prineas RJ. Insulin response in a triethnic population: effects of sex, ethnic origin, and body fat. Miami Community Health Study. Diabetes Care 1997; 20: 1670–1676.
Estrogens protect males from obesity complications
RS Dakin et al

10 Nauzila P, Knauti MJ, Máki M, Laine H, Ruotsalainen U, Teräs M et al. Gender and insulin sensitivity in the heart and in skeletal muscles. Studies using position emission tomography. Diabetes 1995; 44: 31–36.

11 Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88: 2404–2411.

12 Finkelstein JS, Lee H, Burnett-Bowie S-AM, Pallais JC, Yu EW, Borges LF et al. Gonadal androgens, insulin resistance, strength, and sexual function in men. N Engl J Med 2013; 369: 1011–1022.

13 Fox CS, Yang Q, Cupples LA, Guo C-Y, Atwood LD, Murabito JM et al. Sex-specific association between estrogen receptor-a gene variation and measures of adiposity: The Framingham Heart Study. J Clin Endocrinol Metab 2005; 90: 6257–6262.

14 Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M et al. Dystabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004; 89: 61–70.

15 Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B et al. Gonadal steroids and body composition, strength, and sexual function in men. J Clin Endocrinol Metab 1993; 31: 1056–1061.

16 Surwit RS, Wang S, Petro AE, Sanchis D, Raimbault S, Ricquier D et al. Sex-specific association between estrogen receptor-a gene variation and measures of adiposity: The Framingham Heart Study. J Clin Endocrinol Metab 2005; 90: 6257–6262.

17 Holmes MC, French KL, Secll JR. Modulation of serotonin and corticosteroid receptor gene expression in the rat hippocampus with circadian rhythm and stress. Brain Res Mol Res 1995; 76: 180–192.

18 Kotani K, Tchkoukina F, Fujikawa S, Kobatake T, Xiong G, Yoshida S et al. Sexual dimorphism of age-related changes in whole-body fat distribution in the obese Zucker rat. Endocrinology 2000; 141: 560–563.

19 King V, Dakin RS, Liu L, Hadowe P, Walker BR, Secll JR et al. Maternal obesity has little effect on the immediate offspring but impacts on the next generation. Endocrinology 2013; 154: 2514–2524.

20 Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O et al. Tissue-specific dysregulation of cortisol metabolism in human body. J Clin Endocrinol Metab 2001; 86: 1418–1421.

21 Zulu H, Brown WC, Cai Q, Krust A, Chambon P, McGuinness OP et al. Estrogen treatment after ovarectomy protects against fatty liver and may improve pathway-selective insulin resistance and glucose intolerance in mice. Endocrinology 2009; 150: 2109–2117.

22 Heine PA, Folsom AR, White A, Patsch W, Heiss G, Wu KK et al. The Framingham Heart Study. J Clin Endocrinol Metab 2005; 90: 6257–6262.

23 Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M et al. Dystabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004; 89: 61–70.

24 Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B et al. Gonadal steroids and body composition, strength, and sexual function in men. J Clin Endocrinol Metab 1993; 31: 1056–1061.

25 Waget A, Petro AE, Sanchis D, Ricquier D et al. Diet-induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of mice. Proc Natl Acad Sci USA 1998; 95: 4061–4065.

26 Zulu H, Brown WC, Cai Q, Krust A, Chambon P, McGuinness OP et al. Estrogen treatment after ovarectomy protects against fatty liver and may improve pathway-selective insulin resistance and glucose intolerance in mice. Endocrinology 2009; 150: 2109–2117.

27 Heine PA, Folsom AR, White A, Patsch W, Heiss G, Wu KK et al. The Framingham Heart Study. J Clin Endocrinol Metab 2005; 90: 6257–6262.

28 Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M et al. Dystabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004; 89: 61–70.

29 Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B et al. Gonadal steroids and body composition, strength, and sexual function in men. J Clin Endocrinol Metab 1993; 31: 1056–1061.

30 Waget A, Petro AE, Sanchis D, Ricquier D et al. Diet-induced changes in uncoupling proteins in obesity-prone and obesity-resistant strains of mice. Proc Natl Acad Sci USA 1998; 95: 4061–4065.

31 Zulu H, Brown WC, Cai Q, Krust A, Chambon P, McGuinness OP et al. Estrogen treatment after ovarectomy protects against fatty liver and may improve pathway-selective insulin resistance and glucose intolerance in mice. Endocrinology 2009; 150: 2109–2117.
57. Spencer CP, Godsland IF, Cooper AJ, Ross D, Whitehead MI, Stevenson JC. Effects of oral and transdermal 17β-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. *Metabolism* 2000; 49: 742–747.

58. Espeland MA, Hogan PE, Fineberg SE, Howard G, Schrott H, Waclawiw MA et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. *Diabetes Care* 1998; 21: 1589–1595.